VENCLEXTA — Net revenues
Products & Services · Net revenuesAbbVie VENCLEXTA — Net revenues decreased by 2.2% to $710.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 8.4%, from $655.00M to $710.00M. Over 4 years (FY 2021 to FY 2025), VENCLEXTA — Net revenues shows an upward trend with a 11.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration, successful clinical adoption, or expanded indications for the therapy, while a decrease may signal increased competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total gross sales of a specific oncology pharmaceutical product, adjusted for returns, allowa...
Peer comparison
Comparable to product-specific net revenue disclosures for oncology or specialty pharmaceutical assets at peer biopharmaceutical companies.
abbv_segment_venclexta_net_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $435.00M | $492.00M | $488.00M | $473.00M | $505.00M | $515.00M | $516.00M | $538.00M | $571.00M | $590.00M | $589.00M | $614.00M | $637.00M | $677.00M | $655.00M | $665.00M | $691.00M | $726.00M | $710.00M |
| QoQ Change | — | +13.1% | -0.8% | -3.1% | +6.8% | +2.0% | +0.2% | +4.3% | +6.1% | +3.3% | -0.2% | +4.2% | +3.7% | +6.3% | -3.2% | +1.5% | +3.9% | +5.1% | -2.2% |
| YoY Change | — | — | — | — | +16.1% | +4.7% | +5.7% | +13.7% | +13.1% | +14.6% | +14.1% | +14.1% | +11.6% | +14.7% | +11.2% | +8.3% | +8.5% | +7.2% | +8.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is AbbVie's venclexta — net revenues?
- AbbVie (ABBV) reported venclexta — net revenues of $710.00M in Q4 2025.
- How has AbbVie's venclexta — net revenues changed year-over-year?
- AbbVie's venclexta — net revenues increased by 8.4% year-over-year, from $655.00M to $710.00M.
- What is the long-term trend for AbbVie's venclexta — net revenues?
- Over 4 years (2021 to 2025), AbbVie's venclexta — net revenues has grown at a 11.3% compound annual growth rate (CAGR), from $1.82B to $2.79B.
- What does venclexta — net revenues mean?
- The total net sales generated by a specific oncology drug product line.